ImmuPharma (LON:IMM) Shares Down 9.9% - What's Next?

Key Points

• ImmuPharma's shares fell by 9.9% on Wednesday, trading as low as GBX 10.58 ($0.14) after closing at GBX 12.10 ($0.16). This decline occurred despite an increase in trading volume, reaching approximately 14.8 million shares.
• The company reported a negative earnings per share of GBX (0.38) in its latest quarterly earnings, and analysts predict a significant loss of approximately -339.00 earnings per share for the current year.
• ImmuPharma is a specialty biopharmaceutical firm focused on peptide-based therapeutics for autoimmune diseases, with its leading program being P140 (Lupuzor™), aimed at treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) was down 9.9% on Wednesday . The stock traded as low as GBX 10.58 ($0.14) and last traded at GBX 10.90 ($0.15). Approximately 14,800,078 shares traded hands during mid-day trading, an increase of 72% from the average daily volume of 8,597,301 shares. The stock had previously closed at GBX 12.10 ($0.16).

ImmuPharma Stock Performance

The stock has a market capitalization of £54.47 million, a price-to-earnings ratio of -1,224.72 and a beta of 1.53. The company has a fifty day simple moving average of GBX 4.66 and a two-hundred day simple moving average of GBX 3.39.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.